Minimal Residual Disease Testing Current Innovations and Future Directions 1st Editon 2018 Softbound at Meripustak

Minimal Residual Disease Testing Current Innovations and Future Directions 1st Editon 2018 Softbound

Books from same Author: Todd E. Druley

Books from same Publisher: Springer

Related Category: Author List / Publisher List


  • Retail Price: ₹ 7666/- [ 15.00% off ]

    Seller Price: ₹ 6516

Sold By: Book Upload      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 15.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 15.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Todd E. Druley
    PublisherSpringer
    Edition1st Edition
    ISBN9783319948263
    Pages197
    BindingSoftbound
    LanguageEnglish
    Publish YearNovember 2018

    Description

    Springer Minimal Residual Disease Testing Current Innovations and Future Directions 1st Editon 2018 Softbound by Todd E. Druley

    This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of 'difference from normal' flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice. Introduction.- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma.- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies.- Monitoring AML Response Using “Difference From Normal” Flow Cytometry.- ML-DS: A Unique Condition for Measurable Residual Disease Detection.- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.